Passage BIO (PASG) Non-Current Deffered Revenue (2019 - 2021)
Passage BIO (PASG) posted quarterly Non-Current Deffered Revenue of $6.9 million for Q4 2021, up 233.22% year-over-year from $2.1 million in Q4 2020, and up 7.07% quarter-over-quarter from $6.5 million in Q3 2021.
Passage BIO (PASG) Non-Current Deffered Revenue (2019 - 2021) Analysis & Trends
Passage BIO's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $6.9 million for Q4 2021.
- In Q4 2021, Non-Current Deffered Revenue rose 233.22% year-over-year to $6.9 million; the TTM figure through Dec 2021 stood at $6.9 million (up 233.22% YoY), while the FY2021 annual figure was $6.9 million, up 233.22% from the prior year.
- Non-Current Deffered Revenue for Q4 2021 stood at $6.9 million, up from $6.5 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $6.9 million in Q4 2021, with the low at $489000.0 in Q1 2020.
- The 3-year median for Non-Current Deffered Revenue is $2.1 million (2020), against an average of $3.1 million.
- Peak annual rise in Non-Current Deffered Revenue reached 1046.37% in 2021, while the deepest fall reached 233.22% in 2021.
- Passage BIO's Non-Current Deffered Revenue stood at $504000.0 in 2019, then jumped by 312.1% to $2.1 million in 2020, then soared by 233.22% to $6.9 million in 2021.
- Business Quant data shows PASG's Non-Current Deffered Revenue at $6.9 million in Q4 2021, $6.5 million in Q3 2021, and $6.0 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 6.92 Mn |
| Sep 30, 2021 | 6.46 Mn |
| Jun 30, 2021 | 6.01 Mn |
| Mar 31, 2021 | 4.20 Mn |
| Dec 31, 2020 | 2.08 Mn |
| Sep 30, 2020 | 643,000.00 |
| Jun 30, 2020 | 524,000.00 |
| Mar 31, 2020 | 489,000.00 |
| Dec 31, 2019 | 504,000.00 |